Pay in 4 interest-free payments of $5.56 Learn more
Ships within 48 hours · Estimated delivery Aug 18 - Aug 23
This comprehensive resource explores innovative strategies, cutting-edge research, and practical applications of GLP-1 therapies, empowering healthcare professionals to enhance patient outcomes and embrace the future of obesity treatment
G., Miller, R
Cardiovascular diseases (CVDs) are the leading cause of mortality post-transplant, driven by prevalent traditional risk factors, along with complications related to chronic kidney disease (CKD), such as left ventricular hypertrophy and mineral bone disease, which often persist after the transplant [3, 4]
Balette sees often: Patients go on, come off, try again, switch prescriptions or restart when weight begins to return
US$ 25.16
US$ 22.42
US$ 24.88
US$ 20.29
US$ 22.39
US$ 22.51
US$ 27.69
US$ 22.88
US$ 25.83
US$ 28.92
US$ 20.16
